Obesity is a well-known risk factor for breast cancer development and recurrence, and glucagon-like peptide 1 (GLP-1) receptor agonists have emerged as

In patients with obesity, a retrospective study found greater weight loss and lower costs over 2 years after metabolic bariatric surgery than with glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment.

What if the race to get thin was quietly putting health at risk? That question is becoming harder to ignore as glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) such as semaglutide and tirzepatide move from specialist prescriptions for diabetes into mainstream use for rapid weight loss. Once hailed as breakthroughs, these drugs are now linked to a growing list of medical and psychological consequences that many users never anticipated.

Just this week, the World Health Organization released new guidelines recommending GLP-1 therapies as a long-term treatment for adults with obesity.

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

As researchers decipher how GLP-1s affect mental health, experts worry access is outpacing the scientific investigation

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

As the reach of glucagon-like peptide-1 (GLP-1) medications such as Ozempic continue to expand in the United States and Canada, how those drugs influence

World Health Organization Guideline includes conditional recommendation for their use for the long-term treatment of obesity, as part of a comprehensive approach, and calls for urgent action on manufacturing, affordability, and system readiness to meet global needs. WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults

Abstract. The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success,

The World Health Organization (WHO) has for the first time issued guidelines on the use of Glucagon-Like Peptide-1 or GLP-1 therapies for treating obesity.

The World Health Organization (WHO) has come out with the first-ever guidelines on the global use of Glucagon-Like Peptide-1 (GLP-1) medicines for "treating